Search Within

Department of Medicine

Formats
  1. Journal Article (19620)
  2. Meeting Abstract (16084)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22367)
  2. Hematologic Malignancies, Division of (13308)
  3. Center for Hematologic Malignancies (11082)
  4. GSK Faculty (10658)
  5. Survivorship Research (9352)
  6. Division of Subspecialty Medicine (7560)

More Groups

People
  1. Robert Motzer (1251)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1158)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2304)
  6. Nature Publishing Group (2122)

More Publishers

Results (39711)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers
    Meeting Abstract

    Drago, J. Z.; Pareja, F.; Jhaveri, K. L.; Walsh, E. M.; Ku, G. Y.; Maron, S. B.; Janjigian, Y. Y.; Robson, M. E.; Reis-Filho, J. S.; Modi, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Meeting Abstract

    Chew, S.; Ferraro, E.; Chen, Y.; Barrio, A. V.; Kelly, D. W.; Modi, S.; Seidman, A. D.; Wen, H. Y.; Brogi, E.; Robson, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Prospective evaluation of pathologic response with neoadjuvant chemo-immunotherapy in metaplastic breast cancer
    Meeting Abstract

    Abuhadra, N.; Chen, Y.; Plitas, G.; Razavi, P.; Pareja, F.; Reis-Filho, J. S.; Wen, H. Y.; Khan, A. J.; Traina, T. A.; Downs-Canner, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03
    Meeting Abstract

    Krop, I. E.; Wildiers, H.; Hurvitz, S. A.; Cortes, J.; Im, S. A.; Iwata, H.; Andre, F.; Saura, C.; Modi, S.; Kim, S. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC)
    Meeting Abstract

    Tolaney, S. M.; Bardia, A.; Marmé, F.; Cortés, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E. M.; Dalenc, F.; Gómez Pardo, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations
    Meeting Abstract

    Becker, M. N.; Abraham, J.; Kalinsky, K.; Spring, L.; Traina, T. A.; Quill, T. A.; Yardley, D. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers
    Meeting Abstract

    Myers, S. P.; Sevilimedu, V.; Barrio, A. V.; Tadros, A.; Mamtani, A.; Robson, M. E.; Morrow, M.; Lee, M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis
    Meeting Abstract

    Graff, S. L.; Tolaney, S. M.; Hart, L.L.; Razavi, P.; Fasching, P.A.; Janni, W.; Schwartzberg, L. S.; Lanoue, B.; Romero Salas, T.; Khakwani, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Real-world treatment patterns, healthcare resource utilization (HRU) and costs for relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Chimeric antigen receptor T-cell (CAR T) and monoclonal antibodies (MAB) therapies
    Meeting Abstract

    Feng, C.; Murphy, L.; Engel-Nitz, N.; Nguyen, A.; Patel, A.; DuCharme, M.; Fu, C.; Shah, G.
    Value in Health (2023)

    Fulltext@MSK | Save
  • Patient characteristics, treatment patterns, and factors of biomarker testing among patients with advanced non-small cell lung cancer (ANSCLC) in the US, 2012-2020
    Meeting Abstract

    Yang, M.; MacEwan, J. P.; Honnold, R.; McClain, M. R.; O'Hara, R.; Liu, F.; Paik, P.
    Value in Health (2023)

    Fulltext@MSK | Save